Antiphospholipid syndrome (APS), first described in the early 1980s (1), is defined by the presence of antiphospholipid antibodies (aPL) in patients with thrombotic complications and/or adverse pregnancy outcomes (2). This evidence concerns the gene FASLG and autoimmune polyendocrinopathy.